← Back to headlines
Eli Lilly Sales Surge 56% Driven by GLP-1 Demand
Eli Lilly reported a significant 56% surge in sales, primarily attributed to the booming demand for GLP-1 drugs, which overshadowed the impact of lower prices.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
